The largest database of trusted experimental protocols
> Procedures > Health Care Activity > Terminal Care

Terminal Care

Terminal care is the comprehensive care provided to individuals with life-limiting illnesses, focusing on relieving symptoms, improving quality of life, and supporting patients and their families during the final stages of life.
This specialized field encompasses palliative and hospice care, aiming to address the physical, emotional, social, and spiritual needs of terminally ill patients.
Researchers can optimize terminal care research protocols using AI-driven comparisons of published literature, preprints, and patents to identify the best approaches, enhancing the reproducibility and accuracy of their studies and streamlining the research process.
By leveraging PubCompare.ai, researchers can improve the quality of their terminal care research and contribute to advancements in this crucial area of healthcare.

Most cited protocols related to «Terminal Care»

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2013
Concept Formation Conferences Ethics Committees, Research Malignant Neoplasms Palliative Care Patient Transition Specialists Terminal Care Terminally Ill
The overarching goals of the workshop were twofold: 1) to develop treatment algorithms for managing common and rare immunotherapy-related toxicities and 2) to develop standardized templates, including inclusion and exclusion criteria, for irAE management in clinical trial protocols (which will be reported separately). More broadly, participants were charged with describing the spectrum of immune-related toxicities and providing recommendations on recognizing, monitoring and managing these toxicities. To facilitate discussion among experts in different medical fields, attendees broke out into 11 subgroups (‘breakout groups’) that focused on irAEs identified by body system (dermatologic, gastrointestinal, endocrine, pulmonary, rheumatologic, cardiovascular, hematologic, renal, neurologic and ophthalmologic) as well as infusion reactions. These breakout groups were generally supplemented with disease subspecialty expertise focused on the area of interest. Each breakout group received instructions to guide their discussion, a list of recognized toxicities by system, relevant drug package inserts, several key supporting references, and a copy of CTCAE version 4.0. A working draft of the Friends of Cancer Research/Parker Institute for Cancer Immunotherapy guidelines on monitoring, management and follow-up of irAEs from anti-PD-1/PD-L1 agents was also distributed [35 ].
After separate breakout group discussions, one representative from each group presented their recommendations to all participants, and responded to questions and additional suggestions from the wider group. Following the meeting, recommendations made on-site were recirculated by email to participants from each breakout group to ensure all views and opinions were captured. The final recommendations on management of irAEs presented in this paper therefore represent the views of each multidisciplinary expert group. These recommendations are not intended to provide comprehensive medical guidance on the management of disorders that may arise from use of immunotherapy treatment; specialist care should be sought as necessary, and as indicated in treatment-specific guidelines.
Full text: Click here
Publication 2017
Anti-Anxiety Agents Cardiovascular System Disease Management Drug Labeling Friend Human Body Immunotherapy Kidney Lung Malignant Neoplasms Systems, Nervous Terminal Care
Only direct medical costs, including costs of acquiring drugs, costs attributed to the patient’s health state, costs for the management of adverse events (AEs), and costs for end-of-life care, were analyzed (Table 1). The costs are reported in 2019 US dollars and were inflated to 2019 values using the Medical-Care Inflation data set in Tom’s Inflation Calculator.16 According to the IMbrave150 trial report,5 (link) patients in the atezolizumab plus bevacizumab group received atezolizumab (1200 mg) plus bevacizumab (15 mg/kg body weight) intravenously every 3 weeks. Patients assigned to the sorafenib group received sorafenib (400 mg) orally twice daily. Treatment continued until disease progression or unacceptable toxicity or, for the immunotherapy regimen group, until 2 years of follow-up. The prices of atezolizumab, bevacizumab, and sorafenib were collected from public databases.12 ,13 In the US, the prices of ipilimumab, nivolumab, pembrolizumab, and dabrafenib plus trametinib were discounted by 17% to account for contract pricing.17 (link) To calculate the dosage of bevacizumab, we assumed that a typical patient in the US weighed 71.4 kg.18 (link) After disease progression, 69 of 197 patients (35.0%) in the atezolizumab plus bevacizumab group and 73 of 109 patients (67.0%) in the sorafenib group received subsequent active therapy. The costs associated with subsequent active salvage therapy and the greatest supportive care were $108 336 and $37 084 per patient, respectively, which were estimated from a cost-effectiveness analysis of second-line treatments of advanced HCC.14 (link) The monitoring costs for patients with PFD and patients with PD were $245 per month and $15 308 per month, respectively, which were collected from an economic evaluation of sorafenib for unresectable HCC.15 (link) The cost associated with terminal care was $7893 per patient with advanced HCC.14 (link) The analysis included the costs associated with managing grade 3 or higher AEs, which were extracted from the literature (eTable 3 in the Supplement).14 (link),19 (link)Each health state was assigned a health utility preference on a scale of 0 (death) to 1 (perfect health). The PFD and PD states associated with HCC were 0.76 and 0.68,10 (link) respectively, which were derived from a cost-effectiveness analysis considering patients with HCC. The disutility values due to grade 1 or 2 and grade 3 or 4 AEs were included in this analysis.11 (link) All AEs were assumed to be incurred during the first cycle. The duration-adjusted disutility was subtracted from the baseline PFD utility.
Full text: Click here
Publication 2021
atezolizumab Bevacizumab Body Weight dabrafenib Dietary Supplements Disease Progression Hospice Care Immunotherapy Ipilimumab Nivolumab Patient Monitoring Patients pembrolizumab Salvage Therapy Sorafenib Terminal Care trametinib Treatment Protocols
In our study, only direct medical costs were considered, including cost of the drug utilization, PD-L1 test, main AEs, treatments for progression (including active treatments and supportive care), monitoring, and terminal care. Drug prices were estimated from the local bid-winning price (Drugdataexpy ). Only severe AEs with great clinical impact, including anemia, neutropenia, and thrombocytopenia, were calculated because they had a relatively considerable influence on the economic evaluation by decreasing quality of life and increasing utilization of health resource. In addition, AE costs were calculated only once in the first cycle.
Costs of monitoring, AEs, terminal care, and PD-L1 tests were obtained from previously published studies (Wu et al., 2012 (link); Zheng et al., 2018 (link); Jiang and Wang, 2020 (link); Wan et al., 2020 (link)). All patients were assumed to incur one-time PD-L1 test costs in the first cycle and one-time terminal care costs before death. Additionally, costs were discounted at an annual rate of 5% (Sanders et al., 2016 (link)). All costs were converted into United States dollars (USD) by exchange rate: 1 USD = 6.47 CYN. All these data are listed in Table 1. If the ICER is below $32,457 threshold (three times GDP per capita of China in 2020, ¥210,000.00), the treatment is generally considered to be cost-effective.
Full text: Click here
Publication 2021
Anemia CD274 protein, human Disease Progression Head Leukopenia Patients Pharmaceutical Preparations Terminal Care Thrombocytopenia
Inclusion criteria comprised: (1) original research articles with a qualitative component (ie, qualitative, mixed or multimethod studies all accepted); and (2) focus on eliciting prescribers’ perspectives of factors that influence their decision to continue or cease chronically prescribed PIMs (as defined by the authors of each study) in adults.
No limits were placed on the care or practice setting of the patient or prescriber, respectively, or whether the article related to single or multiple medications.
Exclusion criteria comprised: (1) reviews, papers not published in English, and those for which the abstract or full text were not available; (2) focus on medication management decisions in the final weeks of life; (3) focus entirely on initiation of PIMs and (4) reported only quantitative data derived from structured questionnaires.
Publication 2014
Adult Patients Pharmaceutical Preparations Terminal Care

Most recents protocols related to «Terminal Care»

The study recruited participants from a convenience sample of healthy and sick children (8–12 years) and adolescents (13–17 years) in urban Blantyre, Malawi. Children and adolescents attending schools and seeking any health care services through out-patient department at the Queen Elizabeth Central Hospital made up healthy and sick participants, respectively. Written assent and consent was obtained from children and their parents/guardians. For sick participants, the invitation came at the end of clinical care. For healthy participants, invitations were made through the school via a teacher. Participants took the study information leaflets and consent forms home for receipt of consent by their respective parents/guardians and these were brought back to the school the following day. For both sets of participants, once consent was obtained, the questionnaires were distributed by the research team at the end of clinical care or interviews were arranged on a school day. Once the participants completed the questionnaires (in clinic or classroom settings, respectively), the forms were handed over and collected by the study staff. Only children who were literate (as evident from the written consenting process) and therefore able to self-complete the questionnaires were included, but the critically ill were excluded from recruitment. As previous research had revealed a tendency for respondents to avoid the middle responses when completing the adult EQ-5D-5L questionnaire if the EQ-5D-3L is administered first [3 (link)], the EQ-5D-Y-5L was administered before the EQ-5D-Y-3L. This was followed by the self-report Pediatric Quality of Life (PedsQL)™ 4.0 Generic Core Scales for children (8–12 years) or teens (13–17 years). Ethical approval for this study was granted by Ethics Committees at the Malawi College of Medicine (now KUHeS) (P.10/18/2509) and Liverpool School of Tropical Medicine (19-045). A sample size of 200 participants was calculated to provide 80% power, at the two-sided significance level of 0.05, to address the minimum psychometric criteria for convergent and discriminant validity.
Full text: Click here
Publication 2023
Adolescent Adult Child Critical Illness Ethics Committees Generic Drugs Healthy Volunteers Legal Guardians Only Child Outpatients Parent Pharmaceutical Preparations Psychometrics Teens Terminal Care
The questionnaire to solicit healthcare providers’ experience and perspectives was developed by the authors through rigorous literature and law analysis and validated by expert consultation. The consultation panel consisted of oncologists, hospice/palliative medicine specialists, internal medicine specialists and clinical nurses. In addition, a pilot study was also carried out with five physicians and five nurses to further refine items of the questionnaire. The final version of the questionnaire consisted of three categories, i.e., (1) participant characteristics, (2) experience and (3) perspectives. For experience, items relating to giving bad news and POLST-K completion were included (3 items). Under the perspective category, five subcategories were included as follows; (1) awareness of terminal illness care and POLST-K (11 items), (2) opinions about the factors that hinder terminal state diagnosis and giving bad news (13 items), (3) opinions about impediments to EOL discussion per stakeholder (13 items), (4) impediments to completion of POLST-K (6 items), and (5) suggestions and/or recommendations for future EOL care decision-making (10 items) respondents (Additional file 1). Due to the differences in the role of physicians and nurses, items on disease diagnosis and POLST were omitted from the survey of nurse respondents (Additional file 2).
The study was approved by the institutional review board (IRB) of Ulsan University Medical Center where the authors were based. The researchers explained the study purpose to the participants, and all data were collected after respondent’s permission was confirmed utilizing a written informed consent form. All participating healthcare providers completed the questionnaire anonymously and voluntarily. The study was carried out in accordance with the 1995 Helsinki Declaration and the ethical standards of National Research Committee. Data collected were handled confidentially in an approved manner.
Full text: Click here
Publication 2023
Awareness Diagnosis Ethics Committees, Research Health Personnel Hospice Care Muscle Rigidity Nurses Oncologists Physicians Specialists Terminal Care
The cost inputs used in the model, including costs of drug acquisition and administration, disease management, terminal care, and AE management were based on the US clinical practice and are listed in Table 1. It was assumed that 80% of healthcare costs would be paid by healthcare payers. All costs were updated to 2021 US dollars (USD) using the Consumer Price Index, medical care component [28 ].
Publication 2023
Terminal Care
The average weekly costs of disease management in the EF, LR, and DM states were estimated on the basis of an Optum Health Reporting and Insights claims database study by Sieluk et al. [31 (link)]. For patients who remained EF for longer than 10 years, the disease management costs were assumed zero.
A one-time terminal care cost, assumed to include HCRU in the last 30 days of life, was applied upon patients’ death. The cost was estimated by a US Surveillance, Epidemiology, and End Results (SEER) Medicare study amongst patients with metastatic TNBC [32 (link)]. Cost elements included inpatient, emergency care, outpatient, skilled nursing facility, and hospice visits. The resultant cost updated to 2021 USD was $15,779.
Publication 2023
Hospice Care Inpatient Outpatients Patients Service, Emergency Medical Terminal Care
The interview guide consisted of four major chapters with additional sub-parts (see Appendix). The first two major chapters each presented a conversation starter, providing controversial examples from each discipline. The first example introduced a veterinarian and her two clients (mother and adult daughter) in a 5-min video clip from a German reality TV-show (18 ). The scene depicted the vet delivering a terminal diagnosis regarding an elderly dog to her owners in the waiting area of the veterinary practice. The interaction of the vet with the two overwhelmed owners was meant to provide the basis for an exchange about the appropriate setting for delivering diagnoses, the nature of communication in EOL situations, the involvement of clients in therapy decisions, decision-making criteria for elderly patients etc. The video clip was presented to create a shared experience among the participants and to prompt discussion. By starting with the reactions of human medical personnel to the scene, we captured reactions from people outside of the focused field first without already biasing these reactions through the responses of the professionals. This procedure was repeated in the second chapter, only with swapped roles. Here, we introduced participants to a newspaper article about a case of killing on request in the Netherlands (19 ). A 74-year-old woman had ruled in advance (written living will) that she wanted to be euthanized in case of progression of her dementia. Whenever asked, she said she did not want to die yet. Her doctor and family, however, determined one day that the state she had described in her living will had been reached. Therefore, the woman was euthanized, while still verbally complaining and fighting back whilst being administered with the injecting initiating death.
For the third part of the interview guide, three PowerPoint slides were prepared, each introducing a fictitious person uttering a statement regarding (1) terminal care for companion animals, (2) euthanasia of animals, and (3) high-tech veterinary medicine. A translated version of the slides is provided in the Appendix. The slides covered all topics the project team believed to be crucial for debating EOL situations. The fictitious persons on the slides served as outsiders giving their sometimes provocative, polarizing or minority opinion. In contrast to direct questions by the moderator, this method gave the opportunity to strongly (dis)agree with or criticize a position without having to take into account the other person's feelings and judgement. The slides were only used in case the topic had not been addressed earlier in the discussion and there was enough time left.
In the final chapter of the interview guide, participants were instructed to work with Padlet (20 ). Participants were asked as a group to think of the ideal human or companion animal death and assign some key words written on virtual notes to either “human death” or to “animal death” (or both) and discuss their decisions. Participants also had the option to create additional virtual notes with their own key words. A complete list of the provided key words can be found in the Appendix. Our aim was to clarify whether participants perceived the characteristics/conditions of good dying as more or less similar for humans and companion animals in light of their previous discussion.
Full text: Click here
Publication 2023
Adult Children Aged Animals Clip Dementia Diagnosis Euthanasia, Animal Feelings Health Personnel Homo sapiens Light Minority Groups Mothers Patients Pets Physicians Terminal Care Therapeutics Woman

Top products related to «Terminal Care»

Sourced in United States, China, India, Australia, Germany, United Kingdom, Canada, Mexico, Italy
The NextSeq 500 platform is a high-throughput DNA sequencing system designed for a wide range of applications. It utilizes sequencing-by-synthesis technology to generate sequencing data. The platform offers fast and efficient DNA sequencing capabilities.
Sourced in United States
Tenofovir is a laboratory product manufactured by Gilead Sciences. It is a nucleoside reverse transcriptase inhibitor (NRTI) used in research applications. Tenofovir functions by inhibiting the activity of the reverse transcriptase enzyme, which is essential for the replication of certain viruses.
Sourced in United States
The Teledyne Model M is a high-precision laboratory instrument designed for accurate measurement and analysis. It features advanced sensor technology and digital processing capabilities to provide reliable and consistent data. The core function of the Model M is to enable precise quantitative assessment of samples or materials under investigation.
Sourced in Japan
The Automatic Blood Cell Counter is a laboratory equipment designed to measure and analyze various blood cell parameters. It provides accurate and rapid quantification of red blood cells, white blood cells, and platelets in a patient's blood sample. The device utilizes advanced technology to automate the counting and differentiation process, delivering reliable results to support clinical decision-making.
Sourced in United States, United Kingdom, Belgium, Japan
SPSS Statistics for Windows, Version 21.0 is a statistical software package designed for data analysis. It provides a comprehensive set of tools for data manipulation, analysis, and visualization. The software is designed to work on the Windows operating system.
Sourced in United States
SPSS WIN 24.0 is a statistical software package developed by IBM. It provides tools for data management, analysis, and visualization. The software is designed to work on the Windows operating system.
Sourced in United States
Prime 2021.2.2 is a software application designed for DNA sequence analysis and visualization. It provides tools for tasks such as sequence alignment, assembly, and annotation. The software supports a variety of file formats and can be used for a range of molecular biology research applications.
The DMK 41AF02 is a USB 2.0 color industrial camera with a 1/2" Sony ICX205AL CCD sensor. It has a resolution of 1280 x 960 pixels and a maximum frame rate of 30 frames per second. The camera features a CS-mount lens interface and is powered via the USB connection.
Sourced in United States, Austria, Australia
Stata V.15 is a comprehensive statistical software package that provides a wide range of data analysis and management tools. It offers features for data manipulation, statistical modeling, graphics, and programming. Stata V.15 is designed to handle complex data structures and provide advanced analytical capabilities for researchers, analysts, and professionals across various fields.
Sourced in United States, Japan, United Kingdom, Germany, Belgium, Austria, China, Spain, Ireland
SPSS version 24 is a statistical software package developed by IBM. It provides a comprehensive set of tools for data analysis, including techniques for descriptive statistics, regression analysis, and predictive modeling. The software is designed to help users interpret data, identify trends, and make informed decisions based on statistical insights.

More about "Terminal Care"

Terminal care, also known as end-of-life care or palliative care, is a specialized field of healthcare that focuses on providing comprehensive care to individuals with life-limiting illnesses.
This approach aims to relieve symptoms, improve quality of life, and support patients and their families during the final stages of life.
Researchers can optimize their terminal care research protocols by leveraging AI-driven comparisons of published literature, preprints, and patents.
By utilizing tools like PubCompare.ai, researchers can identify the best approaches, enhancing the reproducibility and accuracy of their studies and streamlining the research process.
This crucial area of healthcare encompasses a range of services, including hospice care, symptom management, and emotional/spiritual support.
Researchers may also incorporate related technologies, such as the NextSeq 500 platform for genetic analysis, Tenofovir for HIV treatment, or automated blood cell counters, to improve patient outcomes.
Statistical software like SPSS Statistics, Stata, and SPSS WIN 24.0 can be employed to analyze data and inform research protocols.
Additionally, tools like Prime 2021.2.2 and DMK 41AF02 may be utilized to support the research process.
By optimizing terminal care research and leveraging the latest advancements, researchers can contribute to the ongoing development of this critical field, ultimately enhancing the care and support provided to terminally ill patients and their families.